Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,740
  • Shares Outstanding, K 41,388
  • Annual Sales, $ 10,090 K
  • Annual Income, $ -132,740 K
  • 60-Month Beta 0.97
  • Price/Sales 7.34
  • Price/Cash Flow N/A
  • Price/Book 0.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate 0.38
  • Low Estimate -0.51
  • Prior Year -0.99
  • Growth Rate Est. (year over year) +93.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.39 +31.65%
on 10/21/19
2.00 -8.50%
on 10/25/19
+0.36 (+24.49%)
since 10/15/19
3-Month
0.77 +137.66%
on 08/16/19
2.08 -12.02%
on 09/17/19
+1.03 (+128.84%)
since 08/15/19
52-Week
0.74 +147.30%
on 08/15/19
9.75 -81.23%
on 12/03/18
-6.85 (-78.92%)
since 11/15/18

Most Recent Stories

More News
Aclaris Therapeutics to Present at Upcoming Investor Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at the following conferences:

ACRS : 1.83 (+2.23%)
Aclaris: 3Q Earnings Snapshot

WAYNE, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Thursday reported a loss of $55.3 million in its third quarter.

ACRS : 1.83 (+2.23%)
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the third quarter of 2019 and provided...

ACRS : 1.83 (+2.23%)
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the third quarter 2019,...

ACRS : 1.83 (+2.23%)
Company News for Oct 17, 2019

Companies In The News Are: GM, ACRS, MGM, AVD

MGM : 31.18 (+0.26%)
GM : 36.89 (+0.24%)
AVD : 15.16 (unch)
ACRS : 1.83 (+2.23%)
EPI Health, LLC Acquires Worldwide Rights to RHOFADE(R) from Aclaris Therapeutics, Inc.

CHARLESTON, SC / ACCESSWIRE / October 14, 2019 / EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists, today announced that it...

ACRS : 1.83 (+2.23%)
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

AGN : 183.61 (+0.62%)
DERM : 7.62 (+1.20%)
RIGL : 2.34 (+2.18%)
ACRS : 1.83 (+2.23%)
Aclaris Therapeutics Announces Divestiture of RHOFADE(R)

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE(R) (oxymetazoline hydrochloride) cream,...

ACRS : 1.83 (+2.23%)
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE(R) (oxymetazoline hydrochloride) cream, 1%

Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with Allergan, Inc., has filed a...

ACRS : 1.83 (+2.23%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (NASDAQ: PSMT), Pyxus International, Inc. (NYSE: PYX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Zimmer Biomet...

PSMT : 72.80 (-1.21%)
PYX : 8.69 (-0.80%)
ACRS : 1.83 (+2.23%)
ZBH : 146.78 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade ACRS with:

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

2nd Resistance Point 1.94
1st Resistance Point 1.89
Last Price 1.83
1st Support Level 1.75
2nd Support Level 1.66

See More

52-Week High 9.75
Fibonacci 61.8% 6.31
Fibonacci 50% 5.24
Fibonacci 38.2% 4.18
Last Price 1.83
52-Week Low 0.74

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar